Form 8-K - Current report:
SEC Accession No. 0001193125-26-134916
Filing Date
2026-03-31
Accepted
2026-03-31 17:08:58
Documents
17
Period of Report
2026-03-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d132653d8k.htm   iXBRL 8-K 61240
2 EX-2.1 d132653dex21.htm EX-2.1 627117
3 EX-99.1 d132653dex991.htm EX-99.1 76949
4 EX-99.2 d132653dex992.htm EX-99.2 82088
8 GRAPHIC g14986dsp24.jpg GRAPHIC 14256
9 GRAPHIC g14986dsp24a.jpg GRAPHIC 6474
10 GRAPHIC g14986dsp24b.jpg GRAPHIC 10528
  Complete submission text file 0001193125-26-134916.txt   1213675

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA apls-20260330.xsd EX-101.SCH 2848
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20260330_lab.xml EX-101.LAB 17233
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20260330_pre.xml EX-101.PRE 10810
20 EXTRACTED XBRL INSTANCE DOCUMENT d132653d8k_htm.xml XML 3504
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 26823261
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)